Caricamento...
Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
Lemborexant, a dual orexin receptor antagonist, is approved in the United States, Japan, and Canada for the treatment of insomnia in adults. This phase I, multicenter, open‐label, parallel‐group study assessed the impact of mild or moderate hepatic impairment (HI) on lemborexant pharmacokinetics and...
Salvato in:
| Pubblicato in: | Pharmacol Res Perspect |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8023329/ https://ncbi.nlm.nih.gov/pubmed/33822479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.758 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|